Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax and Ibrutinib for Ibrutinib-Resistant CLL
NCT03943342Phase 2Withdrawn
- Start
- Mar 2020
- Primary completion
- Jul 2021
- Modality
- Small Molecules
01
Overview
Phase 2, open-label trial of venetoclax in chronic lymphocytic leukemia (CLL). Primary endpoints: Overall Response Rate and Rate of Mutation Negative Status. Planned start Mar 2020; status: withdrawn.
02
Drugs
venetoclax
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT03943342.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03943342.